Author:
D’Agati Douglas,Reti Irving M.
Publisher
Springer Science and Business Media LLC
Subject
Behavioral Neuroscience,Public Health, Environmental and Occupational Health
Reference109 articles.
1. Food and Drug Administration. Meeting to discuss the classification of electroconvulsive therapy devices (ECT). Executive summary. 2011: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevices%20Panel/UCM240933.pdf . Accessed 5 Sept 2015. 7 Jan 2016.
2. Food and Drug Administration. Electroconvulsive therapy (ECT) devices for class II intended uses: draft guidance for industry, clinicians and food and drug administration staff. 2015. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm478942.pdf . Accessed 5 Sept 2015.
3. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psych. 2010;68(6):568–77.
4. Reti IM, Baraban JM. Sustained increase in NARP protein expression following repeated electroconvulsive seizure. Neuropsychopharmacology. 2000;23(4):439–43.
5. Reti IM. How does electroconvulsive therapy work? In: Reti IM, editor. Brain stimulation: methodologies and interventions. 1st ed. New Jersey: Wiley Blackwell; 2015. p. 107–22.